This cluster reflects an emerging, paradigm-challenging framework that reconceptualizes chronic primary pain—formally recognized by the WHO in ICD-11 (2019) as a disease entity in its own right—not as an endpoint of cumulative peripheral and central sensitization, but as the downstream manifestation of a more fundamental disruption in bioelectromagnetic coherence occurring at a hypothesized consciousness-neural tissue interface. In this model, the mechanisms that dominate conventional pain research—peripheral sensitization, central sensitization, neuroinflammation, cytokine cascades, glial activation, and epigenetic modifications—are repositioned as sequelae rather than primary drivers, with mitochondrial bioenergetic dysfunction specifically implicated as preceding and priming inflammatory cascades. This represents a significant trajectory shift: from a bottom-up, tissue-damage/inflammation model toward a top-down, systems-coherence model in which electromagnetic synchronization failure cascades into the biochemical and cellular changes traditionally studied as pain "mechanisms."
The supporting evidentiary trend draws on multimodal biomarkers of systemic rhythm disruption: magnetoencephalography-documented thalamocortical dysrhythmia (with therapeutic correction yielding pain relief), circadian rhythm abnormalities, and reduced heart rate variability/cardiac coherence—collectively framed as convergent signatures of a whole-organism coherence deficit rather than isolated organ-specific pathology. This positions cardiac and neural oscillatory measures as potential objective biomarkers or monitoring tools for chronic pain state and treatment response, expanding pain phenotyping beyond self-report and nociceptive pathway assays into biofield and chronobiological domains.
Therapeutically, this trend is anchored by photobiomodulation, whose RCT-demonstrated efficacy is interpreted as indirect clinical validation of an electromagnetic etiology—suggesting that interventions targeting oscillatory/electromagnetic properties of neural tissue may correct upstream coherence disruption rather than merely suppressing downstream inflammatory or sensitization pathways. This foreshadows a broader research and treatment trajectory toward coherence-restoring modalities (light-based, neuromodulatory, cardiac-entrainment, or circadian-targeted therapies) as primary rather than adjunctive treatments for chronic primary pain, alongside diagnostic use of MEG-detected thalamocortical rhythm and HRV/cardiac coherence metrics for stratifying patients and tracking therapeutic correction.
Collectively, the entities describe a mechanistic hierarchy—bioelectromagnetic coherence disruption at the consciousness-neural interface → thalamocortical dysrhythmia, mitochondrial dysfunction, circadian and cardiac coherence abnormalities → central/peripheral sensitization, neuroinflammation, glial activation, cytokine signaling, and epigenetic change → clinical chronic primary pain. This represents a speculative but coherent macro-trend attempting to unify disparate biomarker findings and treatment successes (photobiomodulation, neurofeedback-adjacent MEG correction) under a single upstream causal construct, challenging researchers to test coherence-based interventions and biomarkers as first-line strategies rather than treating inflammation and sensitization as terminal therapeutic targets.